肺炎链球菌对泰利霉素等抗菌药物的体外抗菌活性

In vitro antimicrobial activity of telithromycin against Streptococcus pneumoniae

目的了解本院分离的肺炎链球菌对泰利霉素等抗菌药物的体外抗菌活性。方法对本院2005—2007年从各种临床标本收集的97株肺炎链球菌,用K-B纸片法进行药敏试验,测定这些菌株对泰利霉素等3种新近上市和其他7种临床常用抗菌药物的耐药性。结果97株肺炎链球菌对泰利霉素和利奈唑胺的敏感率均为100%,对喹奴普丁-达福普汀也未发现耐药菌株,只是有18.8%的菌株表现为中介。其他抗菌药物的耐药情况如下:对红霉素、克林霉素、万古霉素、左氧氟沙星、氯霉素和四环素的耐药率分别为60.8%、58.8%、0%、2.1%、12.8%和64.5%,对青霉素的敏感率为85.6%。结论本院尚未用于临床的3种新近上市的抗菌药物泰利霉素、利奈唑胺和喹奴普丁-达福普汀,对本院分离的肺炎链球菌有良好的体外抗菌活性。而上述细菌对红霉素、林可霉素以及四环素有较高的耐药性。

Objective To determine the in vitro activity of telithromycin and other antimicrobial agents against Streptococcus pneumoniae. Methods From 2005 to 2007, 97 S. pneurnoniae isolates were collected and tested for susceptibility by Kirby-Bauer method. Results All these isolates did not show resistance to telithromycin, linezolid, vancomycin, or quinupristin-dalfopristin. About 18.8% of the isolates were intermediately resistant to quinupristin-dalfopristin. Resistance to erythromycin, clindamycin, vancomycin, levofloxacin, tetracycline and chloramphenicol was identified in 60.8 %, 58.8 %, 0 %, 2.1%, 64.5 %, and 12. 8% of the isolates respectively. Conclusions Telithromycin, linezolid, vancomycin, and quinupristin-dalfopristin have good in vitro antimicrobial activity against S. pneurnoniae in our hospital.